AIMS/HYPOTHESIS: Our aim was to study whether glycaemic control differs between individuals with latent autoimmune diabetes in adults (LADA) and patients with type 2 diabetes, and whether it is influenced by time on insulin therapy. METHODS: We performed a retrospective study of 372 patients with LADA (205 men and 167 women; median age 54 years, range 35-80 years) from Swedish cohorts from Skåne (n = 272) and Västerbotten (n = 100). Age- and sex-matched patients with type 2 diabetes were included as controls. Data on the use of oral hypoglycaemic agents (OHAs), insulin and insulin-OHA combination therapy was retrieved from the medical records. Poor glycaemic control was defined as HbA(1c) ≥7.0% (≥53 mmol/mol) at follow-up. RESULTS: The individuals with LADA and with type 2 diabetes were followed for an average of 107 months. LADA patients were leaner than type 2 diabetes patients at diagnosis (BMI 27.7 vs 31.0 kg/m(2); p < 0.001) and follow-up (BMI 27.9 vs 30.2 kg/m(2); p < 0.001). Patients with LADA had been treated with insulin for longer than those with type 2 diabetes (53.3 vs 28.8 months; p < 0.001). There was no significant difference between the patient groups with regard to poor glycaemic control at diagnosis, but more patients with LADA (67.8%) than type 2 diabetes patients (53.0%; p < 0.001) had poor glycaemic control at follow-up. Patients with LADA had worse glycaemic control at follow-up compared with participants with type 2 diabetes (OR = 1.8, 95% CI 1.2, 2.7), adjusted for age at diagnosis, HbA(1c), BMI at diagnosis, follow-up time and duration of insulin treatment. CONCLUSIONS/ INTERPRETATION: Individuals with LADA have worse glycaemic control than patients with type 2 diabetes despite a longer time on insulin therapy.
AIMS/HYPOTHESIS: Our aim was to study whether glycaemic control differs between individuals with latent autoimmune diabetes in adults (LADA) and patients with type 2 diabetes, and whether it is influenced by time on insulin therapy. METHODS: We performed a retrospective study of 372 patients with LADA (205 men and 167 women; median age 54 years, range 35-80 years) from Swedish cohorts from Skåne (n = 272) and Västerbotten (n = 100). Age- and sex-matched patients with type 2 diabetes were included as controls. Data on the use of oral hypoglycaemic agents (OHAs), insulin and insulin-OHA combination therapy was retrieved from the medical records. Poor glycaemic control was defined as HbA(1c) ≥7.0% (≥53 mmol/mol) at follow-up. RESULTS: The individuals with LADA and with type 2 diabetes were followed for an average of 107 months. LADA patients were leaner than type 2 diabetespatients at diagnosis (BMI 27.7 vs 31.0 kg/m(2); p < 0.001) and follow-up (BMI 27.9 vs 30.2 kg/m(2); p < 0.001). Patients with LADA had been treated with insulin for longer than those with type 2 diabetes (53.3 vs 28.8 months; p < 0.001). There was no significant difference between the patient groups with regard to poor glycaemic control at diagnosis, but more patients with LADA (67.8%) than type 2 diabetespatients (53.0%; p < 0.001) had poor glycaemic control at follow-up. Patients with LADA had worse glycaemic control at follow-up compared with participants with type 2 diabetes (OR = 1.8, 95% CI 1.2, 2.7), adjusted for age at diagnosis, HbA(1c), BMI at diagnosis, follow-up time and duration of insulin treatment. CONCLUSIONS/ INTERPRETATION: Individuals with LADA have worse glycaemic control than patients with type 2 diabetes despite a longer time on insulin therapy.
Authors: S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews Journal: Diabetologia Date: 2012-04-20 Impact factor: 10.122
Authors: Olov Rolandsson; Margareta Norberg; Lennarth Nyström; Stefan Söderberg; Maria Svensson; Bernt Lindahl; Lars Weinehall Journal: Scand J Prim Health Care Date: 2012-06 Impact factor: 2.581
Authors: T M E Davis; A D Wright; Z M Mehta; C A Cull; I M Stratton; G F Bottazzo; E Bosi; I R Mackay; R R Holman Journal: Diabetologia Date: 2005-02-24 Impact factor: 10.122
Authors: S Fourlanos; F Dotta; C J Greenbaum; J P Palmer; O Rolandsson; P G Colman; L C Harrison Journal: Diabetologia Date: 2005-09-29 Impact factor: 10.122
Authors: Maike K Kahr; Melissa A Suter; Jerasimos Ballas; Susan M Ramin; Manju Monga; Wesley Lee; Min Hu; Cindy D Shope; Arina Chesnokova; Laura Krannich; Emily N Griffin; Joan Mastrobattista; Gary A Dildy; Stacy L Strehlow; Ryan Ramphul; Winifred J Hamilton; Kjersti M Aagaard Journal: Am J Obstet Gynecol Date: 2015-08-28 Impact factor: 8.661
Authors: Raffaella Buzzetti; Ernesto Maddaloni; Jason Gaglia; R David Leslie; F Susan Wong; Bernhard O Boehm Journal: Nat Rev Dis Primers Date: 2022-09-22 Impact factor: 65.038
Authors: Uazman Alam; Omar Asghar; Ioannis N Petropoulos; Maria Jeziorska; Hassan Fadavi; Georgios Ponirakis; Andrew Marshall; Mitra Tavakoli; Andrew J M Boulton; Nathan Efron; Rayaz A Malik Journal: Diabetes Care Date: 2015-07 Impact factor: 19.112
Authors: Scott J Pilla; Ashok Balasubramanyam; William C Knowler; Mariana Lazo; David M Nathan; Xavier Pi-Sunyer; Jeanne M Clark; Nisa M Maruthur Journal: Autoimmunity Date: 2019-01-02 Impact factor: 2.815
Authors: Lisa Olsson; Valdemar Grill; Kristian Midthjell; Anders Ahlbom; Tomas Andersson; Sofia Carlsson Journal: Diabetes Care Date: 2013-10-15 Impact factor: 19.112